ArticleFrontiers in microbiology2025
Comprehensive regional study of ESBL
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Global research trends, thematic evolution, and one health implications of ESBL-producing Escherichia coli: a bibliometric and science mapping analysis, 2001-2025.Folia microbiologica · 2026Article
- Wildlife as a reservoir of OXA-48-like carbapenemase-producing Enterobacterales.Microbiology spectrum · 2026Article
- Tracking Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Emergence of Fosfomycin Resistance Among ESBL-ProducingHealth science reports · 2026Article
- ESBL and carbapenemase-producing enteric pathogens in animal-origin foods: a one health perspective.Folia microbiologica · 2026Review
- Deciphering the Implications ofPathogens (Basel, Switzerland) · 2026Review
- Virulome Landscape of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Prevalence of extended-spectrum β-lactamase and carbapenemase-producing Escherichia coli from patients, cattle, and environmental sources in northwest Amhara, Ethiopia: a one health approach.BMC microbiology · 2026Article
- Antimicrobial Resistance and ESBL-Associated Predictors Among Uropathogens: A 2019-2024 Isolate-Level Study.Antibiotics (Basel, Switzerland) · 2026Article
- Nanopore sequencing in suitcase lab enables improved detection ofFrontiers in microbiology · 2026Article
- Prevalence of ESBL-ProducingPathogens (Basel, Switzerland) · 2025Article
- Virulence Gene Profiles of Extended-Spectrum β-Lactamase (ESBL)-ProducingVeterinary sciences · 2025Article
- Integration sites ofFrontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The global dissemination of extended-spectrum β-lactamase (ESBL)-producing Methods: Phenotypic and genomic analyses were performed on the isolates to assess ESBL- Results: An overall ESBL- Discussion: These findings underscore the interconnectedness of human, animal, and environmental reservoirs in AMR dissemination. The high genetic diversity observed within farms and the detection of shared clusters across hosts emphasize the need for integrated One Health interventions, including reduced antibiotic use in livestock and enhanced surveillance of high-risk environments. This study provides critical insights into local AMR dynamics, offering a model for regional mitigation strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.